The Ebola is a filovirus whose clinical manifestations are initially non-specific and largely constitutional: fever, chills, fatigue, headache, myalgia, nausea, vomiting, and diarrhea. Soon afterward, the clinical presentation of Ebola virus disease (EVD) progresses to a diffuse, generalized, nonpruritic, maculopapular rash around the trunk, limbs, and mucosal tissue. Ultimately, the symptomology progresses to skin desquamation, fulminant hemorrhagic fever and, oftentimes, death, arising from a pathophysiology that includes lymphocyte cell death, elevated cytokine concentrations, and coagulopathy. With the incubation period of two to 21 days, the case mortality rate has reached as high as 90% in past epidemics to closer to 50% more recently.
It has been noted that individual patients, communities, and response teams composed of healthcare professionals alike must confront a number of challenges in the face of EVD epidemics, including public panic, missteps by authorities, and distrust of healthcare providers fueled by adornment of protective material that renders them unidentifiable and the inability to visit hospitalized loved ones during their sickness or after death prior to internment. The present epidemic is recognized by no less than the director-general of the World Health Organization and others as being the “worst Ebola outbreak in the nearly four-decade history of this disease.”
Please share this program (link) with your colleagues.
Healthcare professionals who may come in contact with patients exposed to ebola or have EVD.
Commercial support for this program has been received from Valeant Pharmaceuticals and Grifols Pharmaceuticals.
Release Date: February 16, 2015 -- Expiration Date: February 16, 2017
Faculty: David Cennimo, MD
By the end of the session the participant will be able to:
ACCREDITATION FOR THIS COURSE HAS EXPIRED. YOU MAY VIEW THE PROGRAM, BUT CME / CE IS NO LONGER AVAILABLE AND NO CERTIFICATE WILL BE ISSUED.
As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review ScientiaCME.
Faculty Disclosure: David Cennimo has no financial relationships to disclose
Disclosures of Educational Planners: Charles Turck, PharmD is an officer and part owner of ScientiaCME, LLC with no relevent financial disclosures.
Commercial Support Disclosure: Valeant Pharmaceuticals and Grifols Pharmaceuticals
*Required to view Printable PDF Version
Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.